FIELD: pharmacology.
SUBSTANCE: invention relates to antivirus derivatives of the general formula I
,
where R1 is selected from C1-6alkyl, R2 is selected from a halogen atom, R3 is selected from OH, H and C1-4alkoxy, R4 is selected from H, C1-6alkyl and halogen-containing C1-6alkyl, R5 is selected from C1-6alkyl and halogen-containing C1-6alkyl. R6 represents phenyl-Y-, where Y is absent or selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C2-6alkenyl-(CO)-, C2-6alkynyl-(CO)-, O, S, amino- and -N (C1-6alkyl). The phenyl is not necessarily substituted with groups selected from C1-6alkyl, halogen atom, nitro, C1-6alkoxy, cyano, C2-6alkenyl, C2-6alkynyl, C1-6acylamino, halogen-containing C1-6alkyl, halogen-containing C1-6alkoxy, amino, N (C1-6alkyl)2 and C1-6alkyl NHCO, or said phenyl is combined with a five- or six-membered cycle with the formation of a five-membered benzo-cycle or six-membered benzo-cycle. Heterocyclyl-Y-, where Y is absent or selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C2-6alkenyl-(CO)-, C2-6alkynyl-(CO)-, O, S, amino- and -N (C1-6 alkyl), or heterocyclyl together with the attachment group Y form the bicyclic heterocycle. Said heterocyclyl is optionally substituted with groups selected from C1-6alkyl, halogen atom, nitro, C1-6alkoxy, cyano, C2-6alkenyl, C2-6alkynyl, C1-6acylamino, halogen-containing C1-6alkyl, halogen-containing C1-6alkoxy, amino, N (C1-6alkyl)2 and C1-6alkylNHCO; C1-6alkyl-OC(O)-C2-6alkenyl- and C1-6alkyl-O-C(O)-C2-6alkenyl-C(O)-, where C1-6alkyl is not necessarily substituted by groups selected from C1-6alkyl, halogen atom, nitro, C1-6alkoxy, cyano, C2-6alkenyl, C2-6alkynyl, C1-6acylamino, halogen-containingC1-6alkyl, halogen-containing C1-6alkoxy, amino, N (C1-6alkyl)2 and C1-6alkyl NHCO; and R7 is selected from H, halogen atom, C1-6alkyl, halogen-containing C1-6alkyl, C1-6alkoxy, halogen-containing C1-6alkoxy, NO2, CN, C1-6alkyl-NH-CO-, hydroxy, mono-C1-6alkylamino, di-C1-6alkylamino, C1-6alkyl-S-, C2-6-alkenyl-S, C2-6alkynyl-S, C1-6alkyl-SO-, C2-6alkenyl-SO-, C2-6alkynyl-SO-, C1-6alkyl-SO2-, C2-6alkenyl-SO2-, C2-6alkynyl-SO2-, C1-6alkyl-OSO2-, C2-6alkenyl-OSO2-, C2-6alkynyl-OSO2-.
EFFECT: new compound, compositions thereof for the treatment of a viral infection of the Flaviviridae family, including viral hepatitis C infection are proposed.
16 cl, 43 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHOSPHORUS(N)AMIDATEACETAL AND PHOSPH(OH)ATACETAL COMPOUNDS | 2019 |
|
RU2796403C2 |
| NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND USE THEREOF IN PHARMACEUTICAL PREPARATIONS | 2013 |
|
RU2701156C2 |
| BENZAZEPINE DICARBOXAMIDE COMPOUND | 2016 |
|
RU2712248C2 |
| MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | 2019 |
|
RU2778294C2 |
| METHOD OF SYNTHESIS OF HERBICIDE SULFONYLUREAS AND N-(PYRIMIDINYL- OR TRIAZINYL)- CARBAMATES AS INTERMEDIATE COMPOUNDS | 1996 |
|
RU2177002C2 |
| SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2020 |
|
RU2824583C2 |
| NAPHTYLENE DERIVATIVE AS CYTOCHROME P450 INHIBITORS | 2004 |
|
RU2363696C2 |
| SUBSTITUTED (2R,3R,5R)-3-HYDROXY-(5-PYRIMIDIN-1-YL)TETRAHYDROFURAN-2-YLMETHYL ARYL PHOSPHORAMIDATES | 2013 |
|
RU2553996C1 |
| β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV | 2016 |
|
RU2764767C2 |
| DERIVATIVES OF 2-SUBSTITUTED PHENYL-5,7-DIHYDROCARBYL-3,7-DIHYDROPYRROLO[2,3-d]PYRIMIDIN-4-ONES, THEIR PREPARING AND PHARMACEUTICAL USING | 2004 |
|
RU2323220C2 |
